Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methocarbamol
Drug ID BADD_D01415
Description Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether.[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with [acetaminophen] or [ibuprofen].[L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Indications and Usage For use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
Marketing Status Prescription; Discontinued
ATC Code M03BA03
DrugBank ID DB00423
KEGG ID D00402
MeSH ID D008721
PubChem ID 4107
TTD Drug ID D0FN7J
NDC Product Code 50268-520; 80425-0138; 68071-4365; 71335-1727; 70518-2209; 61919-616; 68071-2513; 60592-428; 63629-8984; 59651-341; 71335-1795; 70518-3096; 53002-3041; 71288-716; 66267-145; 76420-040; 50090-4793; 61919-610; 55154-2129; 60429-118; 55150-223; 67296-1825; 50090-0184; 61919-627; 70518-1271; 71335-0771; 80425-0171; 50090-5847; 68083-317; 50090-5846; 43353-948; 63629-2420; 70934-114; 0517-1825; 63629-1622; 35356-887; 70518-3117; 51407-467; 71610-599; 71610-598; 10135-665; 0904-7058; 60760-347; 65072-0401; 63629-1244; 50090-0183; 50090-5005; 0641-6217; 0404-9909; 10695-096; 71610-223; 61919-368; 71093-141; 71335-0251; 45865-987; 55700-218; 80425-0020; 61919-148; 25021-675; 66652-1000; 72789-022; 58343-0128; 62207-952; 43353-949; 71610-242; 76385-123; 35573-414; 61919-903; 31722-534; 12666-0003; 52584-073; 63629-2419; 68071-2492; 50090-0182; 50090-0171; 51927-2519; 72789-021; 70518-1554; 68475-002; 67296-1049; 76385-124; 38779-1943; 35573-413; 72789-110; 72789-041; 71610-174; 63629-2417; 72789-012; 63323-778; 70518-2131; 71335-0828; 63629-1124; 70069-101; 50090-0172; 50268-521; 55154-2334; 68071-5222; 63187-087; 35561-212; 50090-4162; 71205-097; 71205-285; 60760-482; 67457-273; 63629-1123; 53002-3590; 69584-612; 52076-6206; 71335-0970; 0143-1292; 55700-890; 55154-2335; 53002-3042; 63629-2418; 72189-284; 58343-0138; 68788-7980; 10135-723; 55700-720; 43547-405; 50090-5006; 63187-130; 71335-0844; 68788-6391; 50090-4309; 71093-140; 59088-724; 71205-103; 55700-716; 50090-1782; 66267-803; 35561-211; 68071-2563; 50090-1781; 68788-7973; 69367-255; 80425-0021; 69584-611; 67296-1662; 0143-1290; 68788-7809; 62991-2895; 43547-226; 63187-019; 70868-910; 0904-7057; 63629-8995; 55154-2130; 43598-839; 60687-568; 10135-664; 51407-468; 50436-0123; 50090-3578; 0641-6103; 50436-9910; 51662-1435; 70868-901; 50090-0170; 45865-100; 31722-533; 66267-146; 68788-9376; 50090-4164; 49452-4575; 71205-019; 50090-5008; 69367-256; 71205-375; 10135-722; 53002-3592; 43063-879; 60429-119; 60687-559; 50090-5907
Synonyms Methocarbamol | Guaiphenesin Carbamate | Carbamate, Guaiphenesin | Parabaxin | Ortoton | Robaxin | Lumirelax
Chemical Information
Molecular Formula C11H15NO5
CAS Registry Number 532-03-6
SMILES COC1=CC=CC=C1OCC(COC(=O)N)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000278%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema10.01.05.009; 23.04.01.0010.000417%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Cardiac arrest02.03.04.0010.000109%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000073%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000109%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.0010.000278%
Coordination abnormal17.02.02.004--Not Available
Death08.04.01.0010.000145%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.000278%
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.0010.000556%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Headache17.14.01.0010.000278%
Hyperhidrosis23.02.03.004; 08.01.03.0280.000278%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000278%
Hypotension24.06.03.002--
Injury12.01.08.004--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages